Citi analyst Geoff Meacham raised his price target on Bristol-Myers Squibb (BMY) to $60, citing a more favorable setup for the sector. The move comes as the drugmaker also announces a partnership with Microsoft to leverage AI for earlier lung cancer detection.
While fully autonomous robotic surgeons remain on the horizon, the foundational technology and data ecosystems being built today are setting the stage for a transformative shift. Two industry giants, Intuitive Surgical and Medtronic, offer investors distinct pathways to capitalize on this evolving landscape.
A catastrophic landslide at a major coltan mine in rebel-held eastern Congo has killed hundreds of informal miners, casting a harsh light on the deadly human cost behind the global tech supply chain.
Realtor.com ranks the Florida Keys among the nation's top luxury markets, where strict development limits and finite land create a high-stakes arena for elite buyers seeking a unique legacy, not just a second home.
A baseless rumor about a potential Osaic-Cetera merger, which spread rapidly through advisor networks, has highlighted the intense pressures and sometimes questionable tactics in today's financial advisor recruiting landscape.
The U.S. Securities and Exchange Commission has appointed Demetrios Logothetis as the new chair of the Public Company Accounting Oversight Board, alongside three new board members, marking a significant leadership shift at the key audit regulator.
The SEC has appointed EY veteran Demetrios Logothetis as PCAOB chair, alongside three new board members, as the audit regulator faces a slashed budget and a pivot toward a lighter regulatory touch.
Plug Power has adjourned a key shareholder vote to February 5th, as it struggles to secure sufficient turnout to approve a measure that would double its authorized shares to 3 billion, a move the company calls essential for its financial stability and growth plans.
President Trump's nominee for Federal Reserve Chair, Kevin Warsh, has championed a 'regime change' at the central bank, focusing on balance sheet reduction and regulatory rollback. However, analysts question his ability to deliver swift interest rate cuts and warn of potential internal conflict.
Newly released federal data confirms Texas led all states in job creation last year, setting new historic highs for total employment, workforce size, and nonfarm jobs in December, even as regional disparities persist.
While small-cap stocks can offer overlooked opportunities, their high-risk nature demands careful scrutiny. We examine three companies where valuation and business concerns suggest caution may be warranted.
While market attention remains fixated on tech giants, the Russell 2000 index harbors promising, lesser-known companies. We examine three firms with distinct competitive advantages in environmental services, digital health, and private markets.
Analyses from multiple artificial intelligence models project divergent paths for Ethereum, Solana, and XRP by 2026, highlighting varying risk-reward profiles based on technological adoption, regulatory landscapes, and market structure.
Medical device maker ResMed (RMD) reported fourth-quarter revenue of $1.42 billion, an 11% year-over-year increase that surpassed Wall Street forecasts. Non-GAAP earnings per share reached $2.81, also topping analyst expectations.
The financial services sector, a traditional engine of economic growth, is underperforming the S&P 500 amid economic uncertainty. We examine three specific stocks—Invesco, Enova International, and Sixth Street Specialty Lending—that investors may want to approach with heightened caution.
Lyft's stock has experienced significant volatility, with recent gains failing to offset broader declines. As the company pushes its autonomous driving and European expansion narrative, investors are left weighing its premium valuation against a challenging competitive landscape and uncertain path to sustained profitability.
Moody's Corporation bolsters its risk analytics arsenal with strategic acquisitions of Numerated Growth Technologies and CAPE Analytics, positioning itself at the center of a private credit market under the regulatory microscope.
The ASX-listed miner's heavily discounted rights issue aims to shore up its balance sheet after a period of steep losses, but analysts are divided on whether the fresh capital marks a new beginning or merely delays deeper challenges.
As the Bank of England prepares for a leadership transition in 2028, a debate ignited by former Fed governor Kevin Warsh gains traction: should central banks shed ancillary roles and return to their core mission of price stability?
Citi raises Lexicon Pharmaceuticals' price target to $2.10, citing strong momentum from its collaboration with Novo Nordisk on obesity drug candidate LX9851 and improved financials.
